EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19
- Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
- Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
- Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate
- Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study
Research & Development
- What the rest of the world can learn from South Korea's COVID-19 response
- COVID-19: Immune system derails
- UK and US healthcare workers report higher rates of COVID-19 compared to general population in early pandemic period
- Single-shot COVID-19 vaccine protects non-human primates
- Immunoprotein impairs Sars-Cov-2
- Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates
- Another mRNA-based vaccine candidate protects animals against SARS-CoV-2
Conferences & Events
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
Regulatory Affairs
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19